MX2024013002A - Compuestos activos frente a bromodominios - Google Patents

Compuestos activos frente a bromodominios

Info

Publication number
MX2024013002A
MX2024013002A MX2024013002A MX2024013002A MX2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A MX 2024013002 A MX2024013002 A MX 2024013002A
Authority
MX
Mexico
Prior art keywords
bromodomains
compounds active
active towards
compounds
towards
Prior art date
Application number
MX2024013002A
Other languages
English (en)
Spanish (es)
Inventor
Garrick Paul Smith
Slavko Rast
Luigi Piero Stasi
Cadahía Jorge Peiró
Visnja Poljak
Original Assignee
Nuevolution As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuevolution As filed Critical Nuevolution As
Publication of MX2024013002A publication Critical patent/MX2024013002A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2024013002A 2022-04-19 2024-10-21 Compuestos activos frente a bromodominios MX2024013002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2250473 2022-04-19
PCT/US2023/019121 WO2023205251A1 (en) 2022-04-19 2023-04-19 Compounds active towards bromodomains

Publications (1)

Publication Number Publication Date
MX2024013002A true MX2024013002A (es) 2024-11-08

Family

ID=86331094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013002A MX2024013002A (es) 2022-04-19 2024-10-21 Compuestos activos frente a bromodominios

Country Status (8)

Country Link
US (1) US20250382308A1 (cg-RX-API-DMAC7.html)
EP (1) EP4511119B1 (cg-RX-API-DMAC7.html)
JP (1) JP2025514712A (cg-RX-API-DMAC7.html)
CN (1) CN119365455A (cg-RX-API-DMAC7.html)
AU (1) AU2023255396A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255932A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024013002A (cg-RX-API-DMAC7.html)
WO (1) WO2023205251A1 (cg-RX-API-DMAC7.html)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
AU2010317096B2 (en) 2009-11-05 2015-03-26 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CA2779355C (en) 2009-11-05 2018-01-16 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
EP2585465B1 (en) 2010-06-22 2014-11-12 GlaxoSmithKline LLC Benzotriazolodiazepine compounds inhibitors of bromodomains
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
HK1211033A1 (en) 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
JP2016504990A (ja) 2012-12-20 2016-02-18 バイエル ファーマ アクチエンゲゼルシャフト Betタンパク質抑制性ジヒドロピリドピラジノン
SG10201900631TA (en) * 2014-08-01 2019-02-27 Nuevolution As Compounds active towards bromodomains
EP3563851B1 (en) * 2016-12-27 2021-04-21 FUJIFILM Corporation Antitumor agent and bromodomain inhibitor

Also Published As

Publication number Publication date
JP2025514712A (ja) 2025-05-09
CN119365455A (zh) 2025-01-24
EP4511119A1 (en) 2025-02-26
WO2023205251A1 (en) 2023-10-26
EP4511119B1 (en) 2026-07-15
US20250382308A1 (en) 2025-12-18
AU2023255396A1 (en) 2024-10-24
CA3255932A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
WO2020106647A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
ZA202404648B (en) Azetidine and pyrrolidine parp1 inhibitors and uses thereof
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
JOP20250258A1 (ar) مثبطات 2-آزا باي سيكلو هبتان kras
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2023009685A (es) Inhibidores de tyk2 y sus usos.
EP4497438A3 (en) Tricyclic parp1 inhibitors and uses thereof
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
WO2023205463A8 (en) Heteroaryl compounds for the treatment of pain
MX2025003571A (es) Inhibidores de tead y metodos de uso de los mismos
WO2022238565A3 (en) Modulators of sortilin activity
MX2023009723A (es) Inhibidores de tyk2 y sus usos.
MX2025010397A (es) Compuestos heterociclicos como inhibidores de la helicasa del sindrome de werner (wrn)
MX2025003515A (es) Moduladores de akt1
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2025001990A (es) Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico
WO2021046315A3 (en) Inhibitors of encephalitic alphaviruses
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
MX2025000659A (es) Compuestos de imidazopiridina, preparacion de los mismos y usos terapeuticos de los mismos
MX2025005713A (es) Moduladores basados en ftalazinona para el tratamiento de enfermedad
MX2023005371A (es) Moduladores de receptor gamma activado por proliferador de peroxisoma (ppar gamma) y metodos de uso.